In this study we addressed whether the proportion and the function of antigen presenting cells (APC), T and NK lymphocytes are modified in the apheresis product of six healthy donors who received a stem cell mobilizing treatment with glycosylated G-CSF at 10 g/kg/day × 5 days s.c. Flow cytometry analysis showed comparable percentages of HLA-DR + (19 ؎ 2% vs 9 ؎ 6%, p = 0.009) and CD122 + (5 ؎ 2% vs 2 ؎ 1%, P = 0.05) cells in G-PBMC. Unfractionated preG-PBMC and G-PBMC were irradiated and tested in primary mixed leukocyte culture (MLC) with two HLA-incompatible responders and induced efficient alloresponses in four of six cases, whereas G-PBMC stimulated poorly in the remaining two cases. Also, in allo-MLC with irradiated G-PBMC we detected lower amounts of IFN-␥ (P = 0.04) and of IL-2 (P = 0.06) than in allo-MLC with preG-PBMC. Furthermore, freshly isolated preG-PBMC and G-PBMC from each donor exerted comparable allogeneic responses to HLA-incompatible irradiated mononuclear cells in all cases. However, G-PBMC showed no NK activity against K562 target cells at any effector:target ratio tested. These data suggest that normal G-PBMC may prevent Th1 alloresponses, maintain efficient alloreactivity to HLA mismatched antigens and have impaired NK activity.
Hematopoietic stem cells mobilized into the peripheral blood with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) have been demonstrated to be as effective as marrow stem cells in reconstituting all blood lineages after allogeneic transplantation. [1] [2] [3] However, leukaphereses collected from normal donors receiving G-CSF contain large numbers of T cells, 4 potentially increasing the risk of acute graft-versus-host disease (aGVHD). Nevertheless, previous reports demonstrated that the incidence and the severity of aGVHD after allogeneic transplantation with G-CSF mobilized peripheral blood mononuclear cells (G-PBMC) are not higher than after allogeneic transplantation with steadystate marrow cells. 3, [5] [6] [7] Experimental studies addressed whether G-CSF may modulate alloimmune responses by directly modifying T cell function or by inducing cell-mediated suppression of T cell alloreactivity. In particular, it was previously demonstrated that aGVHD is more likely due to the activation of type-1 donor cells (secreting IL-2 and IFN-␥) 8 and that pretreatment of mice with G-CSF polarizes donor T cells toward type-2 cytokine production (IL-4 and IL-10), thus reducing aGVHD. 9 , 10 Mielcarek et al 11 showed that G-CSF mobilization increases the frequency of CD14 + monocytes in the blood of normal donors and that a large number of CD14 + cells in the leukapheresis could suppress T cells mainly in a non-contact way, suggesting that this effect may contribute to a lower incidence of aGVHD after G-PBMC allogeneic transplantation. 11 Also, we recently demonstrated that G-PBMC induce a lower allogeneic CD4 + T cell response than purified CD34 + blood cells in primary MLC. 12 Cytolytic cell precursors are present in G-PBMC, 13 however previous data showed that G-CSF could downregulate the NK activity by inhibiting TNF-␣ and IFN-␥ production by NK cells.
14 Nevertheless, Neubauer et al 15 reported a higher proportion of CD8 + , CD56 + and p75 + cells and a more efficient IL-2-induced lymphokine-activated killer (LAK) activity in G-PBMC of patients undergoing an autologous transplantation than in normal controls.
In the present study we analyzed the proportion of antigen presenting cells (APC), T and NK cells, as well as the immunological functions of these cell populations in the blood of healthy donors before and after treatment with G-CSF. Our results suggest that unfractionated G-PBMC may prevent HLA-incompatible type-1 T cell allo-responses. In addition, although maintaining the capacity of responding to alloantigen in MLC, they do not exert NK activity.
Materials and methods

Cell preparation
Blood and apheresis samples were obtained with informed consent from healthy adult peripheral blood stem cell donors. Blood samples were collected before initiating stem cell mobilization with glycosylated G-CSF (lenograstim; Rhone-Poulenc Rorer, Milan, Italy) at a dose of 10 g/kg/day s.c. × 5-6 days and apheresis samples were obtained from the first apheresis on day 5 of treatment. Blood samples from HLA-DR incompatible healthy volounteers were also collected. All samples were separated by centrifugation over Ficoll/Hypaque (Nycomed Pharma, Oslo, Norway). Light density cells were washed twice in RPMI medium enriched with 10% fetal calf serum (FCS) (Seromed Biochrome, Berlin, Germany). Freshly isolated mononuclear cells were then used for cytofluorimetric and functional assays.
Flow cytometry
Flow cytometric analysis was carried out on preG-PBMC and G-PBMC by direct immunofluorescence. Human monoclonal antibodies (mAbs) used in this study are the following: CD3 fluorescein isthyocianate (FITC), CD4 FITC, CD8 FITC, CD16 FITC, CD56 phycoerythrin (PE), CD57 FITC, CD80 (anti-B7-1) PE, CD25 (anti-p55 IL-2 receptor) FITC, CD28 PE, CD14 FITC and CD19 FITC (Becton Dickinson, San José, CA, USA); CD1a PE and CD86 (anti-B7-2) PE (PharMingen, San Diego, CA, USA); CD122 (anti-p75 IL-2 receptor) FITC (Janssen, Brussels, Belgium). Isotype controls IgG1 FITC and PE and IgG2a PE are from Becton Dickinson and IgG2b PE is from PharMingen. Data acquisition and analysis were assessed by Lysis II software (Becton Dickinson).
Primary MLC
Freshly isolated preG-PBMC or G-PBMC were either irradiated with 3000 cGy and used as stimulators, or used as responders in primary allogeneic mixed lymphocyte cultures (MLC). Each donor preG-or G-PBMC were tested with the same two third-party mononuclear cells from two HLA incompatible healthy volounteers. In selected experiments over 90% T cells were isolated from preG-and G-PBMC and from third party mononuclear cells by rosetting with sheep red blood cells, as previously described. 16 Irradiated stimulator and responder cells were resuspended in medium containing RPMI-1640, 25 mm Hepes, 1 U/ml penicillin, 1 g/ml streptomicin and 15% AB human serum (HS) that had been inactivated at 56°C for 30 min. 5 × 10 4 responders were mixed with three dilutions of stimulators, at 1:1 to 1:4 ratio, in round-bottomed 96-well plates for 6 days at 37°C in a 5% CO 2 humidified atmosphere. Cells were pulsed with 1 Ci/well 3 H-thymidine for Table 1 Expression of APC markers on mononuclear cells from healthy donors before (PreG-PBMC) and after (G-PBMC) stem cell mobilizing treatment with G-CSF
PreG-PBMC (%) G-PBMC (%)
P value
Data represent the mean Ϯ s.d. of six separate cases. NS = not significant; NEG = Ͻ0.5%.
18 h before harvest on day 6. The stimulation index (SI) was calculated for each individual experiment as:
NK activity
The NK assay was performed using preG-PBMC or G- 
Cytokine assays
Levels of IL-2, IFN-␥, IL-4 and IL-10 in MLC supernatants were determined by commercially available enzyme-linked immunosorbent assay (ELISA) kits (IL-2: Immunotech, Marseille, France; IFN-␥, IL-4 and IL-10: Endogen, Boston, MA, USA) and a standard curve was generated to determine the cytokine concentration in the sample. Detection limits of the assays were 5 pg/ml for IL-2, Ͻ2 pg/ml for IFN-␥, Ͻ2 pg/ml for IL-4 and Ͻ3 pg/ml for IL-10.
Statistical analysis
Values are mean Ϯ s.d. For statistical analysis, the Wilcoxon test was used. Table 2 Expression of T and NK markers on mononuclear cells from healthy donors before (PreG-PBMC) and after (G-PBMC) stem cell mobilizing treatment with G-CSF 
PreG-PBMC (%) G-PBMC (%) P-value
Results
Phenotypic modifications following G-CSF treatment
The percentage of antigen-presenting cells, T and NK cells among mononuclear blood cells of six healthy donors was evaluated before and after a stem cell mobilizing treatment with G-CSF.
The proportion of cells with potential APC function (ie monocytes, dendritic cells or B cells) expressing markers such as HLA-DR, CD19, CD1a, CD80 and CD86 was similar in preG-PBMC and in G-PBMC (Table 1) . On the contrary, G-PBMC exhibited a significantly increased percentage of CD14 + cells as opposed to preG-PBMC (3 Ϯ 1 vs 17 Ϯ 8, P = 0.003). Further, analysis of T and NK markers in preG-PBMC and in G-PBMC showed no significant differences for the expression of CD3, CD4, CD8 and B7-1/B7-2 ligand CD28. However, the proportions of ␣ and ␤ chain receptors of IL-2 (CD25 and CD122) and of CD16, CD56 and CD57 NK markers were significantly lower in G-PBMC than in preG-PBMC, as shown in Table 2 .
Alloantigen presenting activity of preG-PBMC and G-PBMC
Freshly isolated preG-PBMC or G-PBMC from each donor were irradiated and tested as stimulators of two HLA incompatible responders at different stimulator:responder ratios. In four of six experiments preG-PBMC and G-PBMC induced similar T cell responses from both alloresponders, and one representative example is shown in Figure 1a . In the remaining two cases G-PBMC obtained a reduced allogeneic T cell response of both HLA-incompatible responders as compared to preG-PBMC, as shown in one representative example in Figure 1b . It is worth noting that the proportion of CD14
+ monocytes was similar in samples inducing efficient alloresponses and in those that stimulated allogeneic mononuclear cells poorly (data not shown). These data suggest that different modulation of in vitro allogeneic T cell responses by G-PBMC may not depend upon the expression of HLA-DR, B7-1 or B7-2 costimulatory molecules and/or the number of monocytes in the sample. 
Lack of type-1 T cell alloresponses to G-PBMC
Cytokine production by alloreactive T cells reflects the type-1 or type-2 pattern of response. 17 Thus, to determine whether G-PBMC could drive alloreactive T cells towards a type-1 or a type-2 reaction, we assessed the amount of type-1 (IL-2 and IFN-␥) and type-2 (IL-4 and IL-10) cytokines in the supernatants of primary MLCs where donor preG-PBMC and G-PBMC were irradiated (3000 cGy) and used as stimulators of HLA incompatible mononuclear cells (n = 3 experiments). In the supernatants of alloMLC we detected a significantly lower mean production of IFN-␥ when G-PBMC rather than preG-PBMC were used as stimulators (45 Ϯ 39 pg/ml vs 606 Ϯ 59 pg/ml, P = 0.04). Furthermore, reduced, but not significant (P = 0.06), IL-2 production was observed. Data on type-2 cytokines are variable since IL-10 was reduced in two of three cases and IL-4 resulted decreased in two cases but increased in the other one. Although it cannot be deduced from the release of cytokines by irradiated cells, these results suggest that G-CSF mobilized APC may fail to stimulate type-1 allogeneic T cells in vitro.
Alloreactivity of G-PBMC
Unfractionated preG-PBMC and G-PBMC were tested as responders in primary MLC with irradiated mononuclear cells from two healthy volounteers at different stimulator:responder ratios (1:1 to 1:3). G-PBMC did not show any significantly different alloreactive capacity as compared to preG-PBMC (n = 6 experiments), as shown in one representative example in Figure 2 . In selected experiments we tested freshly isolated purified T cells from preG-PBMC and G-PBMC as responders in MLC and we could observe no difference in the alloresponse of T cells collected before and after G-CSF administration (n = 3 experiments) (data not shown). These results demonstrate that G-CSF treatment in healthy donors of peripheral blood stem cells does not reduce the T cell proliferative response to alloantigen significantly.
Reduced NK activity of G-PBMC
To assess the NK activity before and after G-CSF treatment, freshly isolated preG-PBMC or G-PBMC and thirdparty mononuclear cells as positive controls were tested for their capacity of lysing K562 tumor cells. PreG-PBMC and controls, as expected, exhibited similar NK activity with a percent lysis at an effector:target ratio of 25:1 of on average 27.2 Ϯ 10.4% vs 19.6 Ϯ 7.0%, respectively. On the contrary G-PBMC exhibited no NK activity at any tested concentration, with a percent lysis of 3 Ϯ 2% at an effector:target ratio of 25:1, that was significantly lower than that obtained by controls both at 25:1 (18 Ϯ 4%) (P = 0.0006) and at 6:1 (8 Ϯ 5%) (P = 0.05) effector:target ratio (n = 5 experiments), as shown in one representative example in Figure 3 . Thus, the different proportion of NK cells in preG-PBMC and in G-PBMC (Table 2) may not completely explain the lack of cytotoxic activity of G-PBMC.
Discussion
In this study we demonstrate that G-PBMC may variably stimulate allogeneic T cell proliferative responses but are likely to prevent type-1 alloreactive T cells. Also, T cells in preG-PBMC and in G-PBMC have comparable capacities to respond to HLA incompatible stimulators in alloMLC, while the NK function in G-PBMC is impaired.
The immunologic properties of healthy donors' G-PBMC are still a matter of investigation since allogeneic transplants with these cells induce acute GVHD at rates that are not higher than those observed with marrow cells, despite a significantly greater number of T cells in the graft. 3, [5] [6] [7] Earlier experimental data suggested that type-1 T cells, secreting proinflammatory cytokines (IL-2 and IFN␥), are the principal effectors of the allogeneic T cell reaction characterizing acute GVHD, 18, 19 which, instead, may be prevented by type-2 T cells secreting anti-inflammatory cytokines (IL-4 and IL-10). 8, 9, 20 On the other hand, it is not known if G-PBMC induce type-1 or type-2 alloresponses.
To address whether G-CSF mobilization may affect the immunological properties of donor cells, we compared blood samples obtained before G-CSF treatment and leukapheresis products from six healthy donors by flow cytometry and fuctional assays testing the alloantigen presenting function, the T cell alloreactivity and the NK activity against K562 target cells. Phenotypic characterization of APC provided evidence of a significant increase in the proportion of CD14 + monocytes in G-PBMC with respect to preG-PBMC, as previously reported, 11, 21 although the proportion of cells expressing B7-1 and B7-2 costimulatory molecules was unmodified. Thus, we investigated whether G-CSF treatment may modify the alloantigen presenting function of donor mononuclear cells, tested in primary MLC with two HLA-incompatible responders. In four out of six cases, third-party mononuclear cells responded to preG-PBMC and G-PBMC from the same donor efficiently, while in two cases third-party cells responded briskly to preG-PBMC, but poorly to G-PBMC. However, no difference in the proportion of monocytes was observed in these latter samples as opposed to the others. Moreover, supernatants of alloMLC with irradiated G- PBMC and HLA-mismatched mononuclear responder cells contained small amounts of IFN-␥ and IL-2, as compared to alloMLC where the same responders were tested with the same donors' irradiated preG-PBMC. Thus, it might be hypothesized that after in vivo priming with G-CSF donor APC may prevent host T cells from secreting proinflammatory cytokines, potentially reducing the risk of graft rejection. Further experiments will address whether G-CSFprimed APC may also drive autologous unprimed T cells toward a type 1 or type 2 pattern. Among the mechanisms through which G-CSF may affect APC function there could be the induction of increased blood levels of IL-1 receptor antagonist (IL-1ra) and tumor necrosis factor-receptor (TNFr), and of a decreased release of IFN␥, 22 and/or the post-transcriptional inhibition of TNF-␣ production by monocytes and T cells.
14 This latter mechanism was shown also to affect the alloimmune response of cytotoxic T cells, but could not prevent allogeneic T cell proliferation. 14 Since it has been recently suggested that monocytes collected after mobilization with G-CSF 11 or GM-CSF 23 may suppress autologous T cells in the apheresis product, we also tested whether preG-PBMC and G-PBMC from the same donor include different proportions of T cells and whether these latter might exert different alloreactivity to HLAincompatible irradiated mononuclear cells in primary MLC. No significant differences in the CD4:CD8 ratio, nor in the percentage of CD28 + cells occurred in preG-PBMC and G-PBMC. Unfractionated fresh G-PBMC, and in selected experiments purified T cells as well, showed a proliferative response to alloantigens that was not significantly different from that of homologous preG-PBMC counterparts. In contrast, other investigators reported a decreased alloresponse of G-PBMC as compared to preG-PBMC, hypothesizing that great numbers of CD14 + monocytes would reduce T cell alloreactivity by suppressing the induction of the CD28-responsive complex. 11, 24 Differences from our data may also depend on using cryopreserved T cells, or on the higher doses of G-CSF received by healthy donors in these latter studies. Experiments in the mouse model demonstrated that G-CSF-mobilized T cells secrete type-2 cytokines such as IL-4 and IL-10 upon stimulation with mitogen, 10 or with alloantigen, although they could not document a decreased proliferative response in primary MLC. 9 Interestingly, pretreatment of donors with G-CSF resulted in a longer survival of the host mice due to a reduced acute GVHD. 9, 10 It is conceivable that G-CSF may directly affect the pattern of donor alloreactive T cells and/or may induce APC capable of driving autologous T cells toward type-2 cytokine production, thus partially reducing the risk of acute GVHD.
Finally, G-CSF has been previously shown to affect cytotoxic and NK cells in vitro by downregulating TNF-␣ production.
14 Moreover, G-PBMC from the leukapheresis of patients undergoing autologous transplantation exerted low NK acitvity as compared to non-mobilized monononuclear cells of both peripheral blood and leukaperesis products. 25 Other reports, however, showed that G-CSF 15 or GM-CSF 26 mobilized blood cells contain cytotoxic and lymphokine activated killer (LAK) precursors. A recent report showed that after G-CSF mobilization NK blood cells are functionally abnormal even in the absence of interactions with other cell types. Also, it demonstrated that addition of small amounts of G-CSF might reduce both the growth and the function of NK cells generated in vitro. 27 In this study we demonstrated a significantly reduced proportion of CD16 + , CD56 + and CD57 + NK cells, as well as of cells expressing CD25 and CD122 chains of the IL-2 receptor in healthy donors' leukaphereses. Furthermore, we observed a significantly reduced NK function of G-PBMC against the myeloid leukemia cell line K562 as opposed to third-party mononuclear cells, at any effector:target ratio tested. Thus, modified differentials in preG-PBMC and G-PBMC would not completely explain the abrogation of NK activity in G-PBMC. Although previous data in the autologous setting showed a normalization of the NK function 28 by 15 days after stem cell infusion, it is not known how long the lack of NK activity may last following allogeneic G-PBMC transplantation and whether it may contribute to reducing the potential GVHD and graft-versus-leukemia (GVL) in the early phases after transplant.
Altogether our data suggest that use of allogeneic G-PBSC might result in the induction of host type-2 driven alloreactive T cells, potentially reducing the risk of rejection and facilitating a rapid engraftment. In addition, the number of monocytes in the apheresis does not seem to suppress the proliferative capacity of T cells significantly. Since the development of type-1 or type 2 T cells after allogeneic transplantation is likely to be crucial for a GVL effect, 29 further in vitro studies and the follow-up of transplanted patients will address whether immune modifications of donor cells due to G-CSF treatment may affect the clinical outcome after allogeneic transplantation with G-PBMC.
